Zhejiang Starry Pharmaceutical Co., Ltd. - MacroPolo Zhejiang Starry Pharmaceutical Co., Ltd. - MacroPolo
Healthcare

As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Zhejiang Starry Pharmaceutical Co., Ltd.

Zhejiang Starry Pharmaceutical Co., Ltd.

Company Overview

COMPANY DESCRIPTION

Zhejiang Starry Pharmaceutical primarily supplies active pharmaceutical ingredients (APIs) to domestic and foreign companies. The firm specializes in manufacturing intermediates and APIs for X-ray contrast medium and antibiotics. More than 28% of the firm’s revenue in 2016 came from exports to Europe and Japan.

CHAIRPERSON

Hu Jinsheng

HEADQUARTERS

Taizhou, Zhejiang

PHONE

(576) 8771.8608

EMAIL

yuhaiping@starrypharma.com